
-
Microsoft president urges fast 'resolution' of transatlantic trade tensions
-
Poppies flourish at Tower of London for WWII anniversary
-
US economy unexpectedly shrinks on import surge before Trump tariffs
-
Stocks drop after US economy contracts amid tariffs turmoil
-
US economy unexpectedly shrinks on import surge ahead of Trump tariffs
-
Dravid says Suryavanshi, 14, needs support from fame
-
Arsenal can win 'anywhere' says Merino after Champions League defeat by PSG
-
Bangladesh crush Zimbabwe by an innings in second Test
-
Swiatek recovers against Keys to reach Madrid Open semis
-
Spurs captain Son out of first leg of Europa League semi-final
-
US economy unexpectedly shrinks in first three months of Trump presidency
-
India to ask caste status in next census for first time in decades
-
Burkina junta rallies supporters after claimed coup 'plot'
-
Forest owner Marinakis steps back as European qualification looms
-
US economy unexpectedly contracts in first three months of Trump presidency
-
Bilbao will give 'soul' to beat Man United: Nico Williams
-
Sweden arrests teen after triple killing
-
Pakistan says India planning strike after deadly Kashmir attack
-
Cardinals lay groundwork for conclave, hope for quick vote
-
More automakers drop earnings guidance over tariffs
-
William and Kate release romantic image on low-key anniversary
-
Israel says strikes Syria to shield Druze as clashes spread
-
Champions Cup format 'not perfect' says EPCR boss
-
Iran hangs man as Israeli spy after 'unfair' trial: activists
-
Stock markets mostly rise ahead of US economic data, tech earnings
-
German growth better than expected but tariff turmoil looms
-
Sinner denies beneficial treatment in doping scandal ahead of Rome return
-
Eurozone economy grows more than expected despite US tariff turmoil
-
Toulouse hooker Mauvaka out of Champions Cup semi
-
Germany's next finance minister, 'bridge-builder' Lars Klingbeil
-
Mehidy century puts Bangladesh in command against Zimbabwe
-
Steelmaker ArcelorMittal warns of uncertainty
-
Vietnam's Gen-Z captivated by 50-year-old military victory
-
Moroccan-based cardinal says Church does not need Francis 'impersonator'
-
US official tells UN top court 'serious concerns' over UNRWA impartiality
-
Jeep owner Stellantis suspends outlook over tariffs
-
New Zealand, Phillippines sign troops deal in 'deteriorating' strategic environment
-
Aston Martin limits US car imports due to tariffs
-
Pakistan says India planning strike as tensions soar over Kashmir
-
Australian triple-murder suspect allegedly cooked 'special' mushroom meal
-
Most stock markets rise despite China data, eyes on US reports
-
TotalEnergies profits drop as prices slide
-
Volkswagen says tariffs will dampen business as profit plunges
-
Jeep owner Stellantis suspends 2025 earnings forecast over tariffs
-
China's Shenzhou-19 astronauts return to Earth
-
French economy returns to thin growth in first quarter
-
Ex-Premier League star Li Tie loses appeal in 20-year bribery sentence
-
Belgium's green light for red light workers
-
Haliburton leads comeback as Pacers advance, Celtics clinch
-
Rahm out to break 2025 win drought ahead of US PGA Championship

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
X.Karnes--AMWN